Raymond Debbane, Director at LEXICON PHARMACEUTICALS, INC. (LXRX), bought 2,000 shares at $1.49 ($3K) on 2026-02-25, disclosed to the SEC on 2026-02-27.
Open-market purchase of $3k LXRX by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade B.
Nothing distinguishes this filing.
| Filing → |
| LXRX | BUY | 2026-02-18 | $353K | — | Filing → |
| LXRX | BUY | 2023-10-12 | $2.2M | — | Filing → |
| WW | BUY | 2022-11-15 | $641K | — | Filing → |